Reimagine Care partners with health systems and oncology providers to deliver tech-enabled, at-home cancer care by combining an AI-powered virtual assistant with a 24/7 team of clinical experts. Pulse 2.0 interviewed Reimagine Care chief growth officer John Elliott to learn more.
John Elliott’s Background
Could you tell me more about your background? Elliott said:
“I’ve spent the last 15+ years at the intersection of healthcare and technology — building and scaling teams, opening new markets, and helping companies navigate the complexity of partnering with health systems and oncology practices. I started my healthcare technology career at Cerner, as a Sales Executive focused in device integration across multiple venues of care, including oncology, and from there moved into increasingly specialized roles in oncology-focused health tech — including Carevive Systems and most recently MDClone, where I served as VP of North America. What ties all of it together is a passion for solving hard problems in cancer care with data and technology, and a belief that the best growth strategies are built on genuine clinical and operational understanding, not just pipeline math. I hold an Executive MBA from Washington University in St. Louis and have studied health policy at the Brookings Institute — I also have taught as an adjunct professor at UMKC, which keeps me sharp and connected to the next generation of healthcare leaders.”
Role At The Company
What are your primary responsibilities? Elliott shared:
“As Chief Growth Officer, I own the full go-to-market motion — market strategy, partnerships, health system expansion, and revenue execution. That means everything from refining how we position Reimagine Care in the market to rolling up my sleeves on specific deals. I’m a big believer in a “boots-on-the-ground” approach — you can’t scale something you don’t deeply understand, so I stay close to customers, prospects, and the clinical realities they’re navigating.”
“Reimagine Care was built around a fundamental gap in oncology: patients need continuous, high-quality support between clinic visits, and the current system isn’t equipped to provide it. The founders saw an opportunity to build something purpose-built for oncology — not a generic telehealth or care management platform retrofitted for cancer, but a solution designed from the ground up for the complexity of the oncology experience. Reimagine Care is helping our partners scale existing patient populations, deploy new therapy options, and reduce costs without sacrificing outcomes. That specificity is what drew me here.”
Favorite Memory
What has been your favorite memory working for the company so far? Elliott reflected:
“Two things come to mind. The first is watching Remi, our ai-enabled assistant, genuinely help patients — resolving 54% of engagements autonomously, and reaching 97% resolution when you layer in our Virtual Care Center team. Seeing the patient stories behind those numbers is something I won’t forget. The second is being on site at ACCC and COA and feeling the momentum firsthand — connecting with systems and practices, hearing thought leaders in oncology rally around what we’re doing. It makes the work feel real in a different way.”
Core Products
What are the company’s core products and features? Elliott explained:
“Our flagship product is Remi — an AI-powered virtual oncology care agent that’s purpose-built for cancer patients. Remi extends the care team beyond the four walls of the clinic, providing patients with symptom monitoring and 24/7 support throughout their treatment journey. What makes Remi different isn’t just the technology — it’s the oncology specificity baked into every interaction. This isn’t a generic chatbot; it’s a solution built around the clinical protocols, emotional complexity, and care pathways unique to cancer. We deliver this through our Virtual Care Center model, where Remi works alongside human care coordinators to close the loop between patient and provider.”
Challenges Faced
Have you faced any challenges in your sector recently, and how did you overcome them? Elliott acknowledged:
“The oncology care space is having a real reckoning right now. Health systems are under enormous financial pressure, oncology practices are consolidating, and everyone is being asked to do more with less — while patient volumes and complexity keep rising. At the same time, there’s a lot of noise in the AI-in-healthcare space, which creates healthy skepticism among buyers. The challenge we’ve had to overcome is proving that Remi isn’t just another AI tool — it’s operationally integrated, clinically validated, and actually reduces burden rather than adding to it. We’ve done that by staying close to our health system partners, building trust through outcomes data, and letting the results speak.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Elliott noted:
“We’ve come a long way. The early version of the platform established the core model — virtual care support for oncology patients — but Remi represents a significant leap. We’ve moved into genuinely agentic AI capabilities, meaning Remi doesn’t just respond to patients, it proactively anticipates needs, flags clinical concerns, and coordinates across the care team in ways that weren’t possible before.”
“One area where that evolution is especially meaningful is advanced therapy management (ATM) — specifically CAR-T and BiTE therapies. These are among the most complex, high-stakes treatment protocols in oncology today. Patients receiving CAR-T or bispecific therapies require intensive monitoring for toxicities such as cytokine release syndrome and neurotoxicity, which most commonly could present in the hours to days and weeks following treatment. That’s exactly the gap Remi and ATM are built to address. Our platform can monitor for early warning signs, support protocol-specific care pathways, and escalate to the care team when escalations trigger. This allows for early identification and management of symptoms before an ER visit. As these therapies become more prevalent — and they will — the demand for that kind of intelligent, always-on support is only going to grow. ”
“The shift to “purpose-built for oncology” as our north star has sharpened every product decision we make. Generic care management platforms aren’t equipped to handle the nuance of a CAR-T patient’s post-infusion journey. We are. That specificity is where our evolution has been most deliberate, and where I think we have the clearest competitive advantage.”
Significant Milestones
What have been some of the company’s most significant milestones? Elliott cited:
“A few stand out. Being recognized by Modern Healthcare as one of the Best Places to Work matters to me personally — culture is infrastructure, and that recognition reflects the intentionality this team brings to building something great from the inside out.”
“On the partnership side, signing Moffitt Cancer Center, Tampa General, and Memorial Hermann is a real inflection point. These are among the most innovative health systems in the country, and their confidence in our model is meaningful validation. The recent expansion of our Moffitt relationship, in particular, speaks for itself — they’ve seen what Remi can do and doubled down.”
“The launch of Remi and our move into agentic AI capabilities fundamentally changed what the platform can do — and expanding Remi’s capabilities gave us the speed and ownership to build with the specificity oncology demands.”
Customer Success Stories
Can you share any specific customer success stories? Elliott highlighted:
“I’ll share a patient story, because that’s ultimately what this is all about.”
“Jane is 73, four days into adjuvant chemo for stage 3 triple negative breast cancer. She’s diabetic with a high A1C, her counts are dropping, and she lives 45 minutes from the nearest ED. On a Thursday evening, she notices redness and swelling at her incision site.”
“That’s the moment the existing care system has a gap. And where that gap can cost someone their curative intent treatment plan.”
“Jane texted Remi. Six minutes later, a full triage was complete — not a single human involved. Remi flagged the situation, surfaced an AI-generated summary for our care team, and handed off seamlessly. Brittany, our RN, took over via text. Sarah, our APN, jumped on a video visit. And because Remi had Jane’s chart in context — including her penicillin allergy — the right prescription was sent to her local pharmacy.”
“Thirty-five minutes. First text to prescription.”
“Remi checked in the next two mornings. Redness reduced. No ED visit.”
“That’s what we built Reimagine Care to do — catch the moments that matter before they become emergencies.”
Funding/Revenue
Are you able to discuss funding and/or revenue metrics? Elliott revealed:
“We’re not disclosing specific figures at this time, but I can say the company is well-capitalized and focused on growth. We’re seeing strong demand from health systems and oncology practices, and our pipeline reflects the urgency in the market to find scalable solutions for the gaps in cancer care.”
Total Addressable Market (TAM)
What total addressable market (TAM) size is the company pursuing? Elliott assessed:
“The oncology care management and virtual care market is substantial — and growing. There are approximately 1.9 million new cancer diagnoses in the U.S. each year, with patients navigating months or years of active treatment and survivorship. When you layer in the health system economics — the cost of unplanned ED visits, readmissions, and care gaps — the addressable opportunity runs into the tens of billions. We’re focused on a specific, high-value slice of that: technology-enabled virtual care for oncology that delivers measurable outcomes for both patients and health systems.”
Differentiation From The Competition
What differentiates the company from its competition? Elliott affirmed:
“A few things set us apart. First, specificity — Remi is purpose-built for oncology, not a horizontal care management platform that happens to serve cancer patients. That depth matters clinically and operationally. Second, our model combines AI with human care coordination through our Virtual Care Center — we’re not asking health systems to replace their people, we’re extending their capacity. Third, our partnerships with institutions like Moffitt signal that this isn’t just a promising idea — it’s a validated model. And finally, we’re genuinely at the frontier of agentic AI in oncology, which is where the field is heading. We’re not catching up; we’re helping define what ‘purpose-built AI for cancer care’ looks like.”
Future Company Goals
What are some of the company’s future goals? Elliott emphasized:
“We’re focused on expanding access — getting Remi into more health systems and oncology practices so more patients benefit from continuous, high-quality care between visits. We’re also investing in the data and outcomes layer: the more patients we support, the smarter and more predictive Remi becomes, which creates a compounding advantage over time. Longer term, we see an opportunity to become the new standard of care supporting use cases across the entire oncology ecosystem.”
Additional Thoughts
Any other topics you’d like to discuss? Elliott concluded:
“I’d just say — if you’re paying attention to where AI in healthcare is actually delivering value versus where it’s generating hype, oncology is one of the clearest examples of real impact. The complexity of cancer care creates genuine opportunities for well-designed AI to reduce suffering, improve outcomes, and take burden off already-strained care teams. That’s what gets me out of bed in the morning, and why I’m proud to be building this with the Reimagine Care team.”
